Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer
Jiao Sun, Hongfeng Yuan, Linlin Sun, Lina Zhao, Yufei Wang, Chunyu Hou, Huihui Zhang, Pan Lv, Guang Yang, Ningning Zhang, Wei Lü, Xiaodong Zhang
Abstract
T-cell-mediated antitumor immunity. Notably, combining the PRMT5 methyltransferase inhibitor GSK591 with PD-L1 blockade efficiently inhibited liver cancer growth and improved overall survival in mice. Collectively, our findings reveal the immunosuppressive role and mechanism of PRMT5 in liver cancer and highlight that targeting PRMT5 could boost checkpoint immunotherapy efficacy.
Topics & Concepts
Protein arginine methyltransferase 5ImmunityCancer researchCancerCytotoxic T cellCD8Liver cancerChemistryImmunologyPharmacologyImmune systemBiologyBiochemistryHepatocellular carcinomaGeneGeneticsMethyltransferaseIn vitroMethylationCancer-related gene regulationEpigenetics and DNA MethylationPeptidase Inhibition and Analysis